[Premature rupture of membranes. Prospective study of 218 cases].
OBJECTIVE
To verify the importance of a wait-and-see attitude after premature rupture of the membranes before 34 weeks of amenorrhoea when allowed by the initial physical examination and of an intervening attitude after 34 weeks.


METHODS
A prospective study included 218 cases of premature ruptures of the membranes divided into four groups according to the weeks of amenorrhoea: Group 1, before 32 weeks (n = 11); Group 2, between 32 and 34 weeks (n = 26); Group 3, between 34 and 37 weeks (n = 18); Group 4 after 37 weeks (n = 163).


RESULTS
Before 34 weeks of amenorrhoea, the frequency of premature rupture of the membranes was 0.72%, of germ-positive infants 8% and of infected infants, 11%. Perinatal mortality was 80% and 17.4% of the infants were delivered by cesarian section. Labour was induced in 100 cases (46%), when there was evidence of infection, after a 24-hour waiting period or at 34 weeks of amenorrhoea. When the aspect of the cervix was unfavourable, cervical maturation was induced by intravenous injection of prostaglandins in 75 cases (34%).


CONCLUSIONS
When the rupture occurred before 34 weeks of amenorrhoea and without signs of infection, tocolysis should be entertained. From 28 to 34 weeks and when a favourable outcome is expected, maturation by corticoids can be proposed. When chorio-amniotic infection is suspected and is not confirmed by the laboratory, antibiotic prophylaxy does not appear to improve fetal outcome. The beneficial effect of a conservative wait-and-see attitude before 34 weeks and of intervening thereafter can only be demonstrated with a large randomized study. Thus each case must be managed individually, making it difficult to establish a standard recommended attitude.
Coste
J P
JP
Clinique Gynécologique et Obstétricale, Hôpital Jean-Bernard, Poitiers.
De Meeus
J B
JB
Bascou
V
V
Magnin
G
G
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002585:Cesarean Section; D002821:Chorioamnionitis / Q000453:epidemiology* / Q000628:therapy; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D007239:Infections / Q000453:epidemiology* / Q000628:therapy; D007751:Labor, Induced / Q000379:methods; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology* / Q000628:therapy; D011256:Pregnancy Outcome; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies; D011453:Prostaglandins / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D015145:Tocolysis / Q000379:methods
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D011453:Prostaglandins
La rupture prématurée des membranes. Etude prospective de 218 observations.